Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells

被引:171
作者
Horie, R
Watanabe, T
Morishita, Y
Ito, K
Ishida, T
Kanegae, Y
Saito, I
Higashihara, M
Mori, S
Kadin, ME
Watanabe, T
机构
[1] Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan
[2] Kitasato Univ, Fac Med, Dept Hematol, Kanagawa, Japan
[3] Univ Tokyo, Inst Med Sci, Mol Genet Lab, Minato Ku, Tokyo 1088639, Japan
[4] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
关键词
Hodgkin-Reed-Sternberg cells; CD30; TRAF proteins; NF-kappa B; adenovirus vector;
D O I
10.1038/sj.onc.1205337
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of CD30 and constitutive NF-kappaB activation characterizes tumor cells of Hodgkin's disease (HD), Hodgkin and Reed-Sternberg (H-RS) cells. We report that in H-RS cells overexpression of CD30 leads to self-aggregation, recruitment of TRAF2 and TRAF5, and NF-kappaB activation, independent of CD30 ligand. CD30 and TRAF proteins co-localized in H-RS cell lines and in lymph nodes of HD. An adenovirus-vector carrying a decoy CD30 lacking the cytoplasmic region or a dominant negative IkappaBalpha mutant blocks NF-kappaB activation, down regulates IL-13 expression and induces apoptosis. Thus, in H-RS cells, ligand-independent activation of CD30 signaling drives NF-kappaB activation and this leads to constitutive cytokine expression, which provides a molecular basis for HD. Inhibition of NF-kappaB activation by adenovirus vector-mediated gene transfer may provide a novel strategy of cell- and target molecule-specific therapy for patients with HD.
引用
收藏
页码:2493 / 2503
页数:11
相关论文
共 53 条
[1]  
ADAM D, 1995, J BIOL CHEM, V270, P17482
[2]  
Aizawa S, 1997, J BIOL CHEM, V272, P2042
[3]   A RAPID MICROPREPARATION TECHNIQUE FOR EXTRACTION OF DNA-BINDING PROTEINS FROM LIMITING NUMBERS OF MAMMALIAN-CELLS [J].
ANDREWS, NC ;
FALLER, DV .
NUCLEIC ACIDS RESEARCH, 1991, 19 (09) :2499-2499
[4]   Modulation of life and death by the TNF receptor superfamily [J].
Baker, SJ ;
Reddy, EP .
ONCOGENE, 1998, 17 (25) :3261-3270
[5]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[6]   Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells [J].
Bargou, RC ;
Emmerich, F ;
Krappmann, D ;
Bommert, K ;
Mapara, MY ;
Arnold, W ;
Royer, HD ;
Grinstein, E ;
Greiner, A ;
Scheidereit, C ;
Dörken, B .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :2961-2969
[7]   High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells [J].
Bargou, RC ;
Leng, C ;
Krappmann, D ;
Emmerich, F ;
Mapara, MY ;
Bommert, K ;
Royer, HD ;
Scheidereit, C ;
Dorken, B .
BLOOD, 1996, 87 (10) :4340-4347
[8]   SELF-ASSOCIATION OF THE DEATH DOMAINS OF THE P55 TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR AND FAS/APO1 PROMPTS SIGNALING FOR TNF AND FAS/APO1 EFFECTS [J].
BOLDIN, MP ;
METT, IL ;
VARFOLOMEEV, EE ;
CHUMAKOV, I ;
SHEMERAVNI, Y ;
CAMONIS, JH ;
WALLACH, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (01) :387-391
[9]   Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily [J].
Boucher, LM ;
Marengere, LEM ;
Lu, Y ;
Thukral, S ;
Mak, TW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 233 (03) :592-600
[10]   Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα [J].
Cabannes, E ;
Khan, G ;
Aillet, F ;
Jarrett, RF ;
Hay, RT .
ONCOGENE, 1999, 18 (20) :3063-3070